Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYCCNASDAQ:EGRXNASDAQ:KLTONASDAQ:TENX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYCCCyclacel Pharmaceuticals$1.67+1.8%$3.35$1.36▼$41.12$25.71M0.52111,547 shs49,329 shsEGRXEagle Pharmaceuticals$1.98-1.3%$1.72$1.50▼$2.13$25.65M0.839,314 shs506 shsKLTOKlotho Neurosciences$0.18+1.2%$0.18$0.11▼$7.35$5.76M-1.17.04 million shs494,399 shsTENXTenax Therapeutics$6.04-0.7%$5.81$2.77▼$7.89$25.05M1.92159,163 shs3,321 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYCCCyclacel Pharmaceuticals-0.55%+13.10%-59.20%-68.65%-96.12%EGRXEagle Pharmaceuticals+5.26%0.00%+1.52%+70.94%-42.36%KLTOKlotho Neurosciences-5.25%-9.00%+0.11%-42.60%+17,499,900.00%TENXTenax Therapeutics-2.72%+0.50%+3.93%+1.50%+75.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYCCCyclacel Pharmaceuticals1.3658 of 5 stars0.05.00.00.03.31.70.0EGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/AN/AN/AN/ATENXTenax Therapeutics1.6152 of 5 stars3.60.00.00.03.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYCCCyclacel Pharmaceuticals 2.00HoldN/AN/AEGRXEagle Pharmaceuticals 0.00N/AN/AN/AKLTOKlotho Neurosciences 0.00N/AN/AN/ATENXTenax Therapeutics 3.25Buy$17.50189.74% UpsideCurrent Analyst Ratings BreakdownLatest KLTO, CYCC, EGRX, and TENX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025TENXTenax TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.003/10/2025TENXTenax TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$20.003/10/2025TENXTenax TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 6/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYCCCyclacel Pharmaceuticals$14K1,836.64N/AN/A$0.57 per share2.93EGRXEagle Pharmaceuticals$257.55M0.10$4.94 per share0.40N/A∞KLTOKlotho NeurosciencesN/AN/A$0.19 per share0.95($2.16) per shareN/ATENXTenax TherapeuticsN/AN/AN/AN/A$27.15 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYCCCyclacel Pharmaceuticals-$22.56M-$56.00N/A∞N/A-18,150.00%-1,901.11%-188.23%6/3/2025 (Estimated)EGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/AKLTOKlotho Neurosciences$1.35M-$0.36N/A∞N/AN/AN/A-25.89%N/ATENXTenax Therapeutics-$7.71M-$2.48N/AN/AN/AN/A-46.00%-42.65%8/12/2025 (Estimated)Latest KLTO, CYCC, EGRX, and TENX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/3/2025Q1 2025CYCCCyclacel Pharmaceuticals-$0.29-$0.33-$0.04N/A$0.03 millionN/A5/15/2025Q1 2025KLTOKlotho NeurosciencesN/A-$0.08N/A-$0.08N/AN/A5/14/2025Q1 2025TENXTenax Therapeutics-$0.48-$0.28+$0.20-$0.28N/AN/A4/2/2025Q4 2024CYCCCyclacel Pharmaceuticals-$4.64-$5.28-$0.64-$0.33$0.01 million$0.01 million3/31/2025Q4 2024KLTOKlotho NeurosciencesN/A-$0.07N/A-$0.07N/AN/A3/25/2025Q4 2024TENXTenax Therapeutics-$0.52-$0.18+$0.34-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYCCCyclacel Pharmaceuticals$0.158.98%N/AN/A N/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/ATENXTenax TherapeuticsN/AN/AN/AN/AN/ALatest KLTO, CYCC, EGRX, and TENX DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/28/2025CYCCCyclacel Pharmaceuticals$2.404/29/20254/29/20255/1/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYCCCyclacel PharmaceuticalsN/A0.770.77EGRXEagle PharmaceuticalsN/AN/AN/AKLTOKlotho NeurosciencesN/A0.160.16TENXTenax TherapeuticsN/A38.9538.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYCCCyclacel Pharmaceuticals23.58%EGRXEagle Pharmaceuticals85.36%KLTOKlotho Neurosciences20.07%TENXTenax Therapeutics1.67%Insider OwnershipCompanyInsider OwnershipCYCCCyclacel Pharmaceuticals68.00%EGRXEagle Pharmaceuticals28.90%KLTOKlotho Neurosciences26.70%TENXTenax Therapeutics3.14%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYCCCyclacel Pharmaceuticals1415.40 million4.78 millionOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataKLTOKlotho NeurosciencesN/A32.49 million26.54 millionN/ATENXTenax Therapeutics94.15 million3.28 millionNot OptionableKLTO, CYCC, EGRX, and TENX HeadlinesRecent News About These CompaniesTenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 14, 2025 | globenewswire.comTenax Therapeutics Inc.May 9, 2025 | barrons.comTenax: Phase 3 Heart Failure Program Continues With 2 Key CatalystsApril 16, 2025 | seekingalpha.comTenax Therapeutics files to sell 4.14M shares of common stock for holdersApril 16, 2025 | markets.businessinsider.comTenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceMarch 31, 2025 | globenewswire.comTenax Therapeutics reports Q4 EPS (18c), consensus (43c)March 27, 2025 | markets.businessinsider.comTenax Therapeutics (TENX) Gets a Buy from William BlairMarch 27, 2025 | markets.businessinsider.comTenax Therapeutics: Q4 Earnings SnapshotMarch 25, 2025 | timesunion.comTenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 25, 2025 | globenewswire.comTenax Therapeutics Inc TENXMarch 15, 2025 | morningstar.comRoth MKM Reaffirms Their Buy Rating on Tenax Therapeutics (TENX)March 6, 2025 | markets.businessinsider.comTenax Therapeutics expands Phase 3 LEVEL program for TNX-103March 5, 2025 | markets.businessinsider.comTenax Therapeutics prices 378,346 shares at $6.04 in private placementMarch 5, 2025 | markets.businessinsider.comTenax Therapeutics Announces $25 Million Private PlacementMarch 5, 2025 | globenewswire.comTenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEFMarch 5, 2025 | globenewswire.comTenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare ConferenceMarch 3, 2025 | markets.businessinsider.comTenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech ConferenceJanuary 31, 2025 | globenewswire.comTenax Therapeutics, Inc. Common Stock (TENX) Insider ActivityJanuary 28, 2025 | nasdaq.comTenax Therapeutics Appoints Gillian Andor Vice President, Clinical OperationsJanuary 22, 2025 | markets.businessinsider.com(TENX) Pivots Trading Plans and Risk ControlsJanuary 1, 2025 | news.stocktradersdaily.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKLTO, CYCC, EGRX, and TENX Company DescriptionsCyclacel Pharmaceuticals NASDAQ:CYCC$1.67 +0.03 (+1.83%) As of 12:38 PM EasternCyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.Eagle Pharmaceuticals NASDAQ:EGRX$1.98 -0.03 (-1.25%) As of 10:59 AM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.Klotho Neurosciences NASDAQ:KLTO$0.18 +0.00 (+1.20%) As of 12:37 PM EasternKlotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.Tenax Therapeutics NASDAQ:TENX$6.04 -0.04 (-0.66%) As of 11:31 AM EasternTenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Steel Dynamics Shares Climb After Tariff Announcement Why Super Micro Computer's Upside Could Trigger a Short Squeeze Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Ulta’s Beautiful Q1 Earnings Report Points to More Gains Ahead Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Chewy Stock Gets a New $7.1 Billion Investor and Analyst Upgrade Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
